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Hyperhomocysteinemia occurs in approximately 30% of the patients with premature occlusive arterial disease 
(POAD). Some of these exhibit significantly reduced fibroblast cystathionine (3-synthase (CBS) activities, 
suggesting that they may be heterozygous for CBS deficiency. To test this possibility, we studied cDNA 
derived from four well characterized patients with POAD, exhibiting hyperhomocysteinemia and reduced CBS 
activities, from four normal controls, and from four obligatory heterozygotes for CBS deficiency. Lysates of 
individual colonies of E.coli, containing full-length PCR-amplification products in the expression vector, 
pKK388.1, were tested for CBS activity. cDNA from at least seven of the eight possible independent POAD 
alleles encoded catalytically active, stable CBS which exhibited normal response to both PLP and AdoMet. 
The sequences of all 3'-untranslated regions of all seven isolated POAD alleles were identical to the normal, 
‘wild-type’ CBS sequences. The results of the expression studies were confirmed for one POAD patient by 
determining the full-length cDNA sequences for both alleles; these were entirely normal over the complete 
length of the cDNA. In contrast, the screening method correctly distinguished mutant from normal alleles in 
all four obligatory heterozygotes studied. We conclude that CBS mRNAs from POAD individuals are free from 
inactivating mutations, including all 33 previously identified in heterozygous carriers and homocystinuric 
patients.
INTRODUCTION
Mild hyperhomocysteinemia (HHC) is found in approximately 
one-third of cases of premature occlusive arterial disease 
(POAD) (1) whereas vascular complications such as stroke 
and thromboembolus are common among homocystinuric indi­
viduals (2). As a consequence, elevated plasma levels of 
homocysteine are widely recognized as an independent risk 
factor for such vascular disorders (1). The biochemical and 
cellular participation of homocysteine in this condition is 
unclear, but may involve stimulation of clotting factors V (3) 
and XII (4) together with transcriptional induction of factor 
III (5) and inhibition of protein C conversion (6 ) as well as 
endothelial cell damage by peroxides (7).
Homocysteine is formed subsequently to transmethylation 
from AdoMet. Normally about half of this amino acid is 
resynthesized into methionine while the remainder is trans-
sulfurated to serine by cystathionine f}-synthase (CBS), forming 
cysteine. While blocks in either pathway can lead to elevated 
plasma concentrations of homocysteine, CBS deficiency is 
acknowledged to be the most frequent cause of homocystinuria 
in humans (2). This enzyme is a homotetramer of 63 kDa, 
encoded by a gene located at human 21q22.3 (8 ). Heme and 
pyridoxal 5'-phosphate (9) are required for activity and the 
enzyme is regulated allosterically by AdoMet (10). Homocysti­
nuria which results from CBS deficiency is inherited as an 
homozygous autosomal recessive trait, in which the enzyme 
activity is virtually extinguished (2). We have examined cDNAs 
from a number of homocystinuric patients and identified 33 
distinct pathogenic mutations to date, using a bacterial CBS 
expression system which localizes the position of the mutation 
(11; unpublished).
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Owing to the wide range of normal fibroblast CBS controls, 
it is difficult to differentiate between low normal and hetero­
zygous-deficient enzyme activities; nonetheless, we were inter­
ested in the potential link between heterozygous CBS 
deficiency and HHC/POAD. We therefore decided to employ 
molecular methods to differentiate between normal and mutant 
CBS alleles. These methods circumvent ambiguities originating 
from the normal/heterozygous activity overlap when assayed 
in fibroblast lysates.
To ascertain whether such a link existed, we examined 
cDNA preparations representing seven alleles which could be 
positively identified from four separate patients exhibiting 
HHC/POAD. These patients were selected from 30 candidates 
exhibiting POAD with accompanying HHC, exacerbated by 
methionine loading (12,13). Some of these also possessed 
persistent low levels of CBS in fibroblast cultures, A new 
screening method was developed in which allelic products 
were tested by expression of full-length cDNAs in bacteria 
rather than the segmental replacement method described earlier 
(14). Identification of synonymous mutations facilitated identi­
fication of the separate alleles. Lastly, we sequenced the 3'- 
untranslated regions. We now report that all of the allelic 
products were free from pathogenic mutations and that the 
cDNA preparations expressed normal amounts of CBS in the 
bacterial expression system. It appears highly unlikely that 
pathogenic mutations in the coding region or the 3 '-untranslated 
region are responsible for the HHC observed in these patients.
RESULTS
Subjects studied
Relevant biochemical and clinical findings for the patients 
studied in this report are listed in Table 1. Arteriosclerosis 
was found in all four of the HHC/POAD patients. Peak plasma 
homocysteine levels following a methionine load (12) were 
well above normal for each of the individuals, approximating 
the values observed for obligate heterozygotes. Fibroblast 
cultures from three of the four exhibited CBS activities below 
the normal range.
Screening strategy
We previously developed a bacterial expression method to 
localize pathogenic mutations in cDNA segments from homo- 
cystinuric patients (14). The aim of this study was to test for 
the presence of any inactivating mutations rather than to
localize them. Therefore, we expressed the entire coding region 
of each allele from each patient. The screening strategy is 
summarized in Figure 1.
To date, 33 pathogenic mutations have been identified and 
expressed in E.coli. Only one of these produces appreciable 
CBS activity after expression, approaching 50% of the control 
values. The overwhelming majority, however, completely inac­
tivate the enzyme. Figure 2 illustrates the wide separation in 
CBS activity produced by normal and mutant alleles. Coupled 
with Western analysis of the bacterial proteins, the method is 
highly sensitive; it has never failed to localize mutations in 
CBS from known homozygotes.
Screening for inactive CBS alleles among patients with 
POAD/HHC
The infidelity of r^-catalyzed polymerase chain reaction 
arises principally from the absence of proofreading in Taq 
DNA polymerase. Pyrococcus DNA polymerase proofreads its 
product; accordingly, its substitution for Taq DNA polymerase 
significantly improved PCR fidelity. Whereas PCR of control 
cDNAs with Psp polymerase produced only seven inactive 
clones out of 78 (9%, Fig. 3), similar experiments with Taq 
polymerase yielded five inactive clones out of 14. This 36% 
error rate was too high to allow us to use the Taq enzyme 
for full-length cDNA amplification, accordingly, Psp DNA 
polymerase was used for all experiments.
To ascertain the suitability of this method as a screen for 
heterozygosity, we first tested cDNA derived from known 
heterozygotes (Fig. 3). The frequency of inactive clones from 
four obligate heterozygotes (30/70; 43%) was significantly 
greater than for the controls (7/78; 9%), thus the method 
sensitively distinguishes between these groups. In contrast, 
the frequency of inactive CBS colonies (7/63; 11%) from the 
four HHC/POAD patients was not significantly different from 
the controls. These functional data suggest that it is unlikely 
that the low CBS activities in this group of POAD/HHC 
patients result from mutations in the coding region of the 
CBS gene, assuming that both parental alleles were equally 
represented in the clones which had been analyzed.
Segregation of CBS activity with allelic polymorphisms
To eliminate the possibility that only one allelic product had 
been tested in the expression studies, we examined the cloned 
cDNAs for synonymous mutations in the coding regions (15). 
These markers permitted us to identify both parental alleles in
Table 1. Subjects reported in this study
Subject Sex Fasting HCY (pM) Peak HCY (¡J.M) Site of arteriosclerosis Severity of disease CBS U/mg
3014 F/P 8.9 54.3 Internal carotid and anterior 
cerebral arteries
Transient ischaemic attacks 3.5
3022 F/P 5.7 66.8 Renal, mesenteric and iliac Severe reno-vascular 17
3024 F/P 5.3
arteries hypertension
37.8 Abdominal aorta and femoral 
arteries
Severe dysbasia 3.2
3030 F 9.1 51.0 Cerebral vessels Unknown 5.9
Obligate heterozygotes (n =  10) 4 .2±2 .8 41.0±24.6 0.1-1
Controls (n =  30) 0 .0±0 .9 6.8±1.3 7—™
Homocysteine (HCY) levels before (fasting) and after (peak) methionine challenge (12) are listed for each of the experimental subjects as well as normal 
controls and obligate heterozygotes for CBS deficiency (mean ±  1 standard deviation). F/P: Premenopausal female patients. CBS activities for controls and 
obligate hetero zygotes represent the ranges found in cultured fibroblasts by this laboratory. The majority of controls range from 20-25 U/mg protein.
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individual clones exhibiting normal CBS activity. To carry out 
this test, we analyzed clones derived from obligate hetero­
zygotes as well as from the POAD/HHC patients who were 
informative for these polymorphisms. The results of these 
experiments are summarized in Table 2.
We first tested clones from two obligate heterozygotes for 
.silent T/C substitutions at position 699. The triplets encoded 
at that position (TAC/TAT) both encode tyrosine, therefore the 
protein sequence is unaffected. Of the 12 allelic clones tested 
for one patient (3056) all eight active ones exhibited ‘T’ alleles 
(i.e. T699), whereas all four inactive clones contained ‘C* 
alleles (C699). These results demonstrate that these polymorph­
isms segregated with active and inactive CBS alleles for this 
individual. Similarly, all five active clones from 3065 exhibited 
‘C’ alleles (C699) while all five inactive clones were T ’ 
alleles. These results demonstrate that the PCR-based RFLP 
analytical method used (15) clearly identifies the segregated 
parental alleles.
Both parental alleles were identified among active CBS 
clones derived from three patients with POAD/HHC (Table 
2). The T/C (699) polymorphism was found in allelic products 
from patients 3022 and 3030 whereas another synonymous
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mutation, C1080T (GCC/GCT; Ala 360), was employed to 
distinguish between the allelic products from patient 3014, 
The fourth patient, 3024, did not exhibit these polymorphisms, 
thus it is not certain that both parental alleles were represented 
in the tested clones. The presence of both these alleles in 
active clones unequivocally demonstrates that both parental 
alleles encode enzyme which is catalytically functional, there­
fore neither parental CBS allele encodes protein with patho­
genic mutations in these patients. These results clearly 
differentiate between the obligate heterozygotes whose active 
clones are all of the same haplotype and the POAD patients 
whose active clones were not.
In addition, less than 15% difference was observed in CBS 
activity in C and T alleles from each informative patient. 
The mildest pathogenic mutation studied to date, A114V 
(unpublished), decreases the activity of CBS by at least 
half when the allele is expressed in E.colL The statistically 
insignificant differences between parental alleles (C and T) of 
each vascular patient suggest that it is quite unlikely that these 
individuals are earners for any known mutation, even one so 
mild as A 114V.
DNA sequencing
Primer portion of the cloned cDNAs
The method described in this paper effectively tests the 
majority of the CBS coding region, however, the sequences 
of the primer portions of the cDNA escape definitive scrutiny. 
Accordingly, we sequenced these regions to ascertain whether 
the abnormally low fibroblast levels of enzyme activity 
stemmed from cryptic mutations in the 5 '- or 3 '-ends of the 
coding sequence. These regions were first amplified by PCR.
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Figure 1, Expression system in E.coii. Patient cDNA was amplified by PCR 
using the primers (boxes) described in the text which contained artificial Clal 
and Kpnl sites. The PCR products were restricted with Clal and Kpnl, purified 
and ligated into pKK 388.1 cartridge. Resulting constructs contained cDNA 
sequence which was derived from tested individuals except of the small 
portion incorporated from the primers (shadowed portions). The constructs 
were used Tor E.coit transformation and individual clones were isolated. CBS 
was expressed after induction with IPTG, plasmid DNA of the clones was 
used for restriction analysis, sequencing or synonymous mutation screening.
CBS ACTIVITY (U/ml)
Figure 2. Distribution of CBS activity in separated normal and mutant alleles. 
A total of 211 colonies from normal, obligate heterozygotes and POAD/HHC 
patients were assayed for CBS. Enzyme activity (U/ml lysate) is depicted on 
the abscissa of the histogram; the number o f colonies found in each 100 U/ 
ml division is indicated on the ordinate. Individual colonies were scored as 
inactive within the 0 -100  U/ml division (black). Active colonies exhibited 
CBS values greater than 400 U/ml (slanLed stripes). Four colonies exhibited 
CBS activities between 100 and 400  U/ml (vertical stripes) and were not 
scored. The mean activity for the 44 inactive clones, originating predominantly 
from the obligate heterozygotes, was 10 .8±3 .3  (standard error o f the mean); 
for the 163 normal clones, 8 0 7 ± 1 3 .
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In the 5 '-portion, between six and eight clones derived from 
each patient were chosen for sequencing to limit the probability 
that only one parental allele was tested. The 5'-ends were 
sequenced from nts - 1  to 40, covering the entire region 
occupied by the sense primer. All of the clones in all four 
patients possessed normal cDNA sequence in this region.
Sequencing of the 3 ' untranslated region 
We next searched for mutations in the 3'-sequence of the 
cDNA using a similar strategy. To ensure that both parental 
alleles were represented in the clones, we tested the individual 
colonies for a frequent Msp I polymorphism (T2199C) in the 
3 '-untranslated region. Three of the patients were polymorphic, 
thus only two clones (each representing one allele) were 
chosen for DNA sequencing. The sequence of the plasmids 
harboring these cDNAs was indistinguishable from normal in 
the region homologous to the anti sense primer as well as in 
the 3 '-untranslated region. Four plasmids originating from 
patient 3024, who did not exhibit the MspI polymorphism, 
were also sequenced through the antisense primer region 
further into the 3 ' -untranslated region and were also fully
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Figure 3. Distribution of active and inactive E.coli clones from controls, 
POAD patients, and CBS heterozygotes. Individual E.coli colonies were 
assayed for CBS activity and scored according to the criteria described in the 
legend of Figure 2. The average number of colonies examined for each patienL 
was 18 while the range was 13-25. Each cell line is listed on the left. The 
percentage of positive clones is indicated by the length of the striped bar; 
negative clones by the black bar. The right side of the figure indicates the 
fractions and percentages of negative clones for each group. CBS cDNAs 
containing pathogenic mutations in 32/33 alleles from homoeystinurics produce 
inactive clones.
congruent with the normal allele. These results demonstrate 
the absence of cryptic mutations in both the 5'- and 3 '-coding 
regions and 3' untranslated region of CBS cDNA.
DNA sequencing o f full length cDNA in patient 3014 
To search for other DNA mutations which might be undetect­
able in our screening system, we sequenced the entire coding 
region of CBS cDNA from both alleles of one patient (3014). 
The Ala360 synonymous mutation in the coding region was 
used to identify cDNA clones originating from separate alleles. 
The sequence of both alleles were completely normal over 
their entire coding regions.
Activation of patient CBS by S-adenosylmethionine
Incubation of ‘wild-type’ CBS with AdoMet stimulates the 
enzyme’s activity by increasing its affinity for homocysteine
(10,14). Subtle mutations in the AdoMet binding region, 
displacing the effector from its binding site, might reduce the 
enzyme activity to the levels observed in the fibroblasts 
from the four patients studied. These mutations would be 
accompanied by a lack of response of the enzyme to AdoMet. 
We measured CBS activity in fibroblast lysates, and in bacterial 
extracts, incubated with added AdoMet varying from 0-500 
liM and calculated the activation constant, K.,ct, for AdoMet 
to determine whether such mutations might exist. Figure 4 
depicts the results of the fibroblast study. Although the basal 
activities differed considerably, CBS in each patient cell extract 
responded to AdoMet similarly. Both the 15 |iM AdoMet 
activation constant and the 2.5-fold increase in enzyme activity 
were identical for the patients and controls. These results 
indicate that the AdoMet binding domains for CBS in all 
patient lines are intact and that the endogenous AdoMet 
concentration in the cell cultures are similar in each cell line.
CBS, expressed in E.coli, behaved similarly when incubated 
with varying concentrations of AdoMet (data not shown). 
These results demonstrate unequivocally that both alleles of 
each patient encode CBS with identical behavior towards 
AdoMet; accordingly, the wide variation in the CBS activities of 
these patients cannot be ascribed to defective AdoMet binding.
Analysis of cloned CBS by Western blotting
Since all of the CBS clones were free from pathogenic 
mutations, we suspected that the low intracellular CBS activit­
ies might be attributed to decreased amounts of normal enzyme 
subunits. The volumes of fibroblast extracts were adjusted so 
that each sample contained equal amounts of enzyme activity.
Table 2. Distribution of CBS activity between parental alleles
Cell line C-Alleles 
No. clones Activity
T-Allcles 
No. clones Activity
Obligate 3056 4 o ± o a 8 829 ± 7 8 “
heterozygotes 3065 5 679±51a 5 0 ± 0 !l
POAD/HHC 3014 2 469±57b 5 540 ± 80b
patients 3022 2 I020±53b 6 950 ± 87”
3030 3 793±122h 5 916± 58h
Full-length CBS cDNAs were prepared from fibroblast mRNAs for each cell line listed in the table, cloned into pKK388.1, resolved and expressed in transformed
E.coli as described in Materials and Methods. Separate parental alleles (C-alleles or T-alleles) were identified by the presence of common synonymous mutations: 
C1080T (Ala360), 3014; C699T(Tyr233), all others. No synonymous mutations were found for 3024. The activity columns refer to mean CBS activity ± I 
standard deviation of the mean for the number of clones indicated in the columns to the left. aC and T alleles which differ significantly by Student’s /-test 
(p<0.001). bC and T alleles not significantly different (p>0.2).
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Immunoprecipitates of these samples were analyzed by Western 
blotting to estimate the actual amount of enzyme in each. 
Comparable band intensities resulted from identical amounts 
of enzyme activity even though 2 0 -fold more total cellular 
protein was required for the defective cell lines (Fig. 5, upper 
panel). We conclude that the specific activity of the pure 
enzyme molecules is constant in each fibroblast line and that 
the low CBS activity found in these lines results from decreased 
amounts of enzyme molecules rather than impaired catalytic 
activity, These conclusions were further supported by the 
following bacterial studies.
All seven separated alleles were examined by Western 
blotting of the E.coli lysates. Whereas the quantity of crude 
fibroblast protein required to produce a constant (2 U) amount 
of CBS was quite variable, bacterial lysates were far more 
consistent, even when the colonies expressed separate CBS 
alleles (Fig. 5, lower panel). These results demonstrate that 
the specific activity of the cloned CBS subunits does not vary 
in clones derived from separated parental alleles. Additionally, 
they reveal that the enzyme proteins encoded by each allele 
are equally stable in E.coli, as would be expected if each allele 
encoded an identical product.
DISCUSSION
The purpose of this research was to ascertain whether the 
hyperhomocysteinemia observed in the four patients studied 
originated from mutations in the CBS coding region. At least 
seven of the eight possible alleles were examined and did 
not contain mutations. We therefore conclude that the HHC 
observed in these four individuals does not stem from defective
CBS protein. CBS binds three cofactors in addition to its two 
substrates: PLP (16), AdoMet (10,14), and heme (9). All of 
these affect CBS activity. PLP is an active participant in the 
reaction (16), AdoMet stimulates the enzyme allosterically
(10,14), while heme is required for both PLP binding and 
enzyme activity (9). Fibroblast cultures from three of the four 
patients exhibited low enzyme activities upon repeated assay. 
It is unlikely that these resulted from reduced PLP affinity 
since the enzyme responded normally when assayed in both 
the presence and absence of this cofactor (data not shown); 
additionally, altered PLP affinity is associated with mutations 
in the coding region (17) and none were found. AdoMet 
sensitivity, likewise, was unaffected for all of the preparations 
(Fig. 4). CBS specific activity depends upon its saturation with 
heme (9). This porphyrin binds tightly to CBS and is evidently 
inserted either concurrently with or shortly after synthesis. 
Addition of heme to enzyme incubations is without effect on 
either crude or pure preparations of the enzyme (9) so it is 
not possible to test directly the affinity of CBS for heme. 
Western analyses of the proteins from fibroblasts, however, 
demonstrated that the amount of CBS protein closely correlated 
to the levels of CBS activity (Fig. 5) so it is likely that the 
heme saturation is equal for the normal and HHC/POAD 
samples. These results imply that the reduced amounts of 
CBS in the fibroblast samples resulted from altered enzyme 
expression rather than a mutation in its structure.
The clear separation of activity between normal and mutant 
alleles in this screening method (Fig. 2) greatly simplifies 
identification of bacterial colonies harboring plasmids con­
taining mutant CBS cDNAs. The substitution of Psp DNA 
polymerase, which proofreads its products, for Taq, which 
does not, significantly improved the sensitivity of the method. 
Fidelity of the screening method depends directly upon fidelity
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Figure 4. Activation of CBS in fibroblast extracts by AdoMet. Fibroblast 
extracts were assayed for CBS activity in the presence of AdoMet (exogenous 
concentrations were 0, 10, 50 and 500 | l iM ).  Numbers on the bottom signify 
the cell line examined, 1996 is a control cell line. The individually shadowed 
columns represent the fraction of maximum CBS activity (maximum was at 
500 jiM AdoMet concentration). The maximum CBS activities obtained for 
each cell line were K.6 U/mg total cellular protein for 3014; 24 for 3022; 5.4 
for 3024; 19.4 for 3030; and 72.8 for 1996.
Figure 5. Western analyses. The upper panel shows 2 units of CBS activity 
immunoisolated from fibroblast extracts and subjected to Western analysis. 
Numbers at the bottom of this panel represent the amounts of total cellular 
protein used to immunoisolate the identical CBS activities. The lower panel 
compares intensity of bands originating from each cloned parental allele 
(signified as letters a and b next to the cell line number) when 2 units of CBS 
were immunoisolated, run on SDS/PAGE and blotted. Total bacterial protein 
subjected to the analysis is indicated at the bottom.
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of the polymerase. This was tested by PCR of normal CBS 
cDNA sequences. Using Taq polymerase, less than 2/3 of the 
PCR products encoded active CBS when a normal plasmid 
template was amplified. More than 90% of the Psp polymerase 
control products were active.
All of the known mutations associated with homocystinuria 
impact considerably on CBS activity expressed in transformed 
bacteria (11; unpublished). There was no significant difference 
in the frequency of inactive clones between the HHC/POAD 
patient and the normal control groups; although considerable 
variation was observed between individuals in the obligate 
heterozygote group. In addition, screening for synonymous 
mutations allowed us to show that individual parental CBS 
alleles were tested for pathogenic mutations in three of the 
patients. All of the coding regions of these sequences were 
free from pathogenic mutations. This was not the case for the 
obligate heterozygotes which were unequivocally differentiated 
from the controls. We subsequently separated the allelic 
products from the obligate heterozygotes and identified the 
mutations in the abnormal strand (14,21; unpublished). This 
method permits unequivocal identification of heterozygous 
carriers for homocystinuria for the first time.
Since at least three of these patients are homozygous for 
normal CBS, their hyperhomocysteinemias evidently stem 
from other factors. Homocysteine, once formed, can either 
serve as a substrate for transsulfuration or be resynthesized 
into methionine (2). Although the most frequent cause of 
homocystinuria is CBS deficiency (2), the condition may 
arise from inadequate methionine resynthesis as well (18,19). 
Defects in cobalamin metabolism (19) or methylenetetra- 
hydrofolate reductase insufficiency (18) could precipitate 
hyperhomocysteinemia in these subjects. Other defects could 
include vitamin malnutrition with or without attenuated heme 
biosynthesis, or concurrent low expression of key enzymes 
such as methylenetetrahydrofolate reductase and CBS. The 
rate of methionine resynthesis is currently under investigation 
to evaluate its contribution to these patients’ condition.
Lastly, it is important to note that there is a strong overlap 
of the normal and heterozygote CBS activity ranges in cultured 
fibroblasts (20). Three of the patients studied were below the 
normal range while the fourth patient was well within it. Our 
initial intent was to evaluate whether they were heterozygous 
for CBS deficiency. With this publication, we demonstrate that 
they were all homozygous for normal CBS. In many cases, 
fibroblast cultures have been in passage for some time. In 
others, the phase of the culture may not be reliably determined. 
Each of these conditions can affect the level of enzyme assays, 
including those for CBS. Considerable variability in CBS 
activity may occur within cultures of apparently healthy 
fibroblasts as well. These considerations together with our 
results indicate that fibroblast CBS activities alone cannot be 
used to assess the CBS zygosity of a patient, even when 
accompanied by hyperhomocysteinemia; accordingly, the dia­
gnosis of individuals suspected of being carriers of homocystin­
uria must be based on analysis of their nucleic acid sequences.
MATERIALS AND METHODS
Patients and cell lines
Cell lines 3014, 3022, 3024, and 3030 from POAD/HHC patients used in 
these studies originated from two clinical and biochemical studies described
elsewhere (12,13). Cell lines 2047, 2103 and 3077 were from controls and 
367, 3009, 3056 and 3065 were from mothers of homocystinuric patients. 
The mutations in these obligate heterozygotes were I278T, E239K, G307S, 
and R336C, respectively (14,21; unpublished). Fibroblasts were cultured in 
MEM with 10% fetal calf serum, nonessential amino acids, glutamine, 100 
U/ml of kanamycin and 100 fig/ml of streptomycin.
PCR amplification of cDNA
DNA was amplified using Pywcoccus sp . GB-D DNA polymerase (Psp, Deep 
Vent Polymerase, New England Biolabs, Beverly, MA) or with Taq polymerase 
as noted in the results section. Complementary DNA was synthesized from 
mRNA as described previously (14). Diluted target strands were completely 
denatured prior to PCR by heating to 95°C for 3 min and rapidly chilling in 
an ice/water bath.
Each 100 |il reaction mixture for PCR with the Deep Vent enzyme contained 
1 |il of cDNA, 1 X Deep Vent buffer (NEB), 300 |iM of each dNTPs, 80 pmol 
of both sense and antisense primers (described above), 4%  dimethylsulfoxide 
and 8 mM M gS04. Conditions for Taq-mediated PCR were: 2.5 jal cDNA, 
10 mM TRIS.HC1 (pH 8.4), 50 mM KCI, 0.01% gelatin, 200 \iM  of each 
dNTPs, 1.5 mM MgCl2 and 80 pmol of both the sense and andsensc primers 
contained in a total of 100 \i\. Primer sequences for both sets of PCRs were: 
Sense primer 5'-TACGATCGATAAGGAGGTTTAAACCATGGGTTCTG- 
AGACCCCCCAG-3'. The bold portion of the sense primer hybridized to 
the 5' coding region of CBS cDNA, The underlined codon following the 
initiator ATG was changed from proline to glycine to complete a Nco I site; 
this change coincidentally increased the activity of CBS. The nonhybridizing 
portion of the primer contained a prokaryotic ribosome binding site and a Cla 
I site; Antisense primer 5'-TACGGGTACCAGCGCTCCGGACTTCACTT- 
CTGG-3'. The bold portion was complementary to the 3' region o f the cDNA 
whereas the remainder contained an artificial Kpn I site.
PCR was conducted in a Techne PHC-1 thermocycler with block temperature 
control when the Deep Vent enzyme was used. The reaction mixture was 
preheated to 80°C/5 min and 1 U of Psp polymerase was added to each Lube. 
The temperature was cycled 30 times (96°C/1 min; 61°C/1 min; 72°C/2.3 
min) to amplify target DNA. The Techne thermocycler produced uniform 
results with this enzyme whereas the reactions did not proceed well with the 
Hybaid TR1, used for Tag-amplified PCR.
The Hybaid TR1 thermal reactor with tube temperature monitoring was 
employed for Taq DNA polymerase PCR. Enzyme was added after preheating 
to 80°C/5 min, then the mixture was cycled as follows: 1 cycle (94°C/3 min, 
50°C/1 min, 72°C/3 min), 4 cycles (94°C/1.5 min, 50°C/1 min, 72°C/3 min), 
24 cycles (94°C/1.5 min, 55°C/1 min, 72°C/2 min) and final cycle (94°C/1.5 
min, 55°C/1 min, 72°C/4 min).
PCR products were purified, restricted with Cla I and Kpn I, gel purified, 
and ligated in gel into similarly prepared pKK388.1 (14). Individual, ampicillin- 
resistant colonies of transformed DH5aFI’Q E.coli were subsequently used 
to express CBS or prepare plasmid DNA.
CBS expression in E.coli
Enzyme activity was measured in 20 fil lysates of transformed cells grown 
from individual colonies after incubation with IPTG (isopropylthio-(3-D- 
galactoside, GIBCO BRL, Gaithersburg, MD) as fully described elsewhere
(14). One unit of CBS activity was defined as 1 nmol of cystathionine 
produced in 1 h at 37°C. This radiometric assay can reliably dctect enzyme 
activity as low as 0.03 U (100 CPM above background).
Analysis of synonymous mutations
Three synonymous mutations in the coding region of CBS cDNA and one 
polymorphism in the 3' untranslated region (G573A; C699T; T1080C; T 2199C) 
were analyzed by a PCR-based RFLP method described elsewhere (15).
cDNA sequencing
A 5'- portion of CBS cDNA in all four PAD/HHC patients was amplified 
by PCR between nucleotides —2 and 272 using the sense primer 5'-
CGTAGAATTCCAGCACCATCTGTCCGGTCCCA-3' t together with the 
antisense primer 5'-TACGATCGATTCAGG-CCGAACTTCTTCCCAAT-3'. 
Reaction conditions were identical to those described for Psp PCR except 
that 4 mM MgS04 was used and 30 cycles of amplification (96°C, 1 min; 
55°C, 1 min; 75°C, 30 s) were carried out. PCR products were restricted with 
Cla I/Eco RI, subcloned into a pBlueScript K S(+) cartridge and the resulting 
plasmid preparations used for sequencing. A 3 '-portion of CBS cDNA of all 
four patients between nucleotides 1462 and 2316 was similarly amplified with
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polymerase using the sense primer P5, 5'-CGTAGAATTCAAAGTCAT- 
C T A C A AGCAGTTC-3', and the antisense primer P6, 5'-TACGATCG- 
ATGTGTGATTCCATTTATATG-AAATGTCC-3'. Thermocycling conditions 
were: 30 cycles of 96°C, 1 min; 64°C, 1 min and 72°C, 54 s. The entire CBS 
cDNA coding regions between nucleotides 22 and 1646 from both alleles of  
patient 3014 were cloned and sequenced.
Other methods
Magic MiniPrep kits (Promega, Madison, WI) were used to prepare plasmid 
DNA. Restriction endonucleases and T4 ligase were purchased from NEB 
(Beverly, MA). DNA was sequenced by the dideoxy method (23) using the 
CircumVent kit (NEB). Competent cells (DH5aFTQ) were obtained from 
Gibco BRL.
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